SCHEMBL31637530

SCHEMBL31637530

CSc1ncc2ccc(=O)n(C3CC3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 18/20 0.49
CDK2 P24941 15/20 0.49
CDK4 P11802 12/20 0.49
CCND2 P30279 9/20 0.49
CCND3 P30281 9/20 0.49
CCNA2 P20248 5/20 0.49
FGFR1 P11362 3/20 0.49
FGFR2 P21802 3/20 0.49
FGFR4 P22455 3/20 0.49
FGFR3 P22607 3/20 0.49
CCNE1 P24864 13/20 0.46
CDK6 Q00534 9/20 0.46
CCNT1 O60563 3/20 0.46
CDK9 P50750 3/20 0.46
CCNA1 P78396 4/20 0.46
CCNE2 O96020 3/20 0.44
PAK4 O96013 1/20 0.44
PAK1 Q13153 1/20 0.44
PKN1 Q16512 1/20 0.44
CCNB2 O95067 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828611 1.00 CCND1 (0.49) CCND1CDK2CDK4CCND2CCND3
SCHEMBL574660 0.94 CCND1 (0.56) CCND1CDK2CDK4CCND2CCND3
SCHEMBL29990953 0.94 CCND1 (0.56) CCND1CDK2CDK4CCND2CCND3
SCHEMBL4828470 0.93 CCND1 (0.57) CCND1CDK2CDK4CCND2CCND3
SCHEMBL29507717 0.88 CCND1 (0.42) CCND1CDK2CDK4CCND2CCND3
SCHEMBL22860605 0.85 CCND1 (0.40) CCND1CDK2CDK4CCND2CCND3
SCHEMBL31153373 0.84 CDK2 (0.58) CCND1CDK2CDK4CCND2CCND3
SCHEMBL19857375 0.84 CDK2 (0.58) CCND1CDK2CDK4CCND2CCND3
SCHEMBL4713281 0.82 L3MBTL1 (0.47) CCND1CDK2CCNE1CDK6
SCHEMBL24669667 0.82 CDK2 (0.53) CCND1CDK2CDK4CCND2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137393-A1 BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASES 2, 4, AND 6 VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed